Unknown

Dataset Information

0

Telbivudine in chronic lymphocytic myocarditis and human parvovirus B19 transcriptional activity.


ABSTRACT:

Aims

Myocarditis is often associated with parvovirus B19 (B19V) persistence, which can induce vascular damage. Based on the antiviral and anti-inflammatory properties of telbivudine, we aimed to evaluate its efficacy to protect B19V-infected endothelial cells in vitro and to treat chronic lymphocytic myocarditis patients with B19V transcriptional activity.

Methods and results

We evaluated the endothelial-protective potential of telbivudine in human microvascular endothelial cells-1, which were infected with B19V. Treatment with 10 ng/mL of telbivudine decreased the B19V-induced endothelial cell apoptosis and endothelial-to-mesenchymal transition. Along with this finding, telbivudine reduced the expression of transforming growth factor-β1 and of tenascin-C. The endothelial-protective properties of telbivudine were also found in tumour necrosis factor-α-stressed human microvascular endothelial cells-1. In addition, oxidative stress in angiotensin II-stressed and transforming growth factor-β1-stressed HL-1 cardiomyocytes and fibroblasts, respectively, was reduced upon telbivudine treatment, illustrating that telbivudine exerts multimodal protective effects. Based on these in vitro findings, four patients severely suffering from an endomyocardial biopsy-proven myocarditis associated with B19V transcriptional activity (VP1/VP2-mRNA positive) were treated with telbivudine (600 mg/dL) for 6 months in a single-patient-use approach. Follow-up biopsies 6 months after treatment showed that VP1/VP2-mRNA levels and CD3 cells decreased in all patients and were associated with an improvement in ejection fraction and New York Heart Association class. These findings were paralleled by a drop in tenascin-C expression as shown via matrix-assisted laser desorption ionization-imaging mass spectrometry.

Conclusions

Telbivudine exerts endothelial-protective effects in B19V-infected endothelial cells and improves chronic myocarditis associated with B19V transcriptional activity. These findings will be further evaluated in the clinical exploratory trial: the PreTopic study.

SUBMITTER: Van Linthout S 

PROVIDER: S-EPMC6165949 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3999338 | biostudies-literature
| S-EPMC88596 | biostudies-literature
| S-EPMC8571226 | biostudies-literature
| S-EPMC511008 | biostudies-literature
| PRJEB26712 | ENA
| S-EPMC6256668 | biostudies-literature
| S-EPMC5623651 | biostudies-literature
| S-EPMC1642163 | biostudies-literature
| S-EPMC2965155 | biostudies-literature
| S-EPMC104439 | biostudies-literature